The number of diabetics in the world continues to increase, and in Chartres, Novo Nordisk continues to grow… The Danish giant, number one in the treatment of diabetes in the world and the largest private employer in Eure-et- Loir, has just announced that it is investing 130 million euros on this site to triple its production capacity for FlexTouch injector pens.
The presentation of the project took place in the presence of the Minister of Industry Roland Lescure, on January 19, while the street was mobilizing against pensions. “I insisted on being present. During the pension reform, the industry does not stop,” he said.
New skills in demand
The group will create two assembly lines and two additional pen packaging lines by expanding its last building. The construction site has already started, but it will be necessary to wait until mid-2025 for the industrial tool to be operational.
To run these lines, Novo Nordisk, which currently employs 1,450 people, will have to recruit again. It provides for the opening of 150 positions, engineers, technicians, operators, etc. “The growth in production has an impact on many services. We therefore need to find new skills in many areas”, specifies the general manager of Novo Nordisk France Etienne Tichit.
Opened in 1961, the Chartres plant is the group’s second production site after Denmark. In twenty years, the Danish giant, which provides about 50% of insulin in the world, has invested 500 million euros. And he already announces that he is thinking about new projects.